Synaptogenix, Inc. — Form 10-Q summary
Reporting period: Quarter and six months ended June 30, 2023. The request metadata names TAO Synergies Inc., but the supplied filing is for Synaptogenix, Inc. (Nasdaq: SNPX); confirm the intended company.
Business context
Synaptogenix is a clinical-stage biopharmaceutical company focused primarily on Bryostatin-1 for Alzheimer’s disease (AD), with potential development programs in Fragile X syndrome and multiple sclerosis (MS). The company reported no revenue in the supplied financial statements and continues to fund operations and development from cash and financing.
Financial results and liquidity
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 | Comparison |
|---|---|---|---|
| Revenue | No revenue reported | No revenue reported | — |
| Research and development expense | $0.31 million | $1.18 million | Down 84.2% and 65.4%, respectively, year over year |
| General and administrative expense | $1.52 million | $3.57 million | Down 17.9% and 2.3%, respectively |
| Net loss | $4.09 million | $5.81 million | Quarterly loss increased 9.1%; six-month loss decreased 17.4% |
| Net loss attributable to common stockholders | $10.21 million | $12.19 million | Includes preferred dividends and a $5.69 million deemed dividend from preferred-stock extinguishment |
| Cash and cash equivalents | $32.90 million at June 30, 2023 | Down from $37.48 million at December 31, 2022 | |
| Cash used in operating activities | $2.94 million for the six months | Compared with $6.01 million in the 2022 period | |
| Working capital | $30.64 million at June 30, 2023 | Down from $37.27 million at year-end 2022 |
There is no conventional borrowing balance identified in the supplied balance sheet. However, the company has redeemable Series B preferred stock, accrued redemption payments, and warrant and embedded derivative liabilities. Total liabilities were $6.53 million, including $2.63 million in derivative liability and $1.13 million in warrant liability. No operating margin is meaningful because no revenue is reported.
Material changes and notable items
- Operating expenses fell as the AD confirmatory Phase 2 trial was largely concluded by the end of 2022 and the open-label dose-ranging study was discontinued. R&D expense for the first half fell to $1.18 million from $3.43 million.
- The confirmatory Phase 2 AD study did not meet statistical significance on its primary endpoint. The company reported positive findings in several secondary and exploratory analyses for a subgroup with baseline MMSE-2 scores of 10–14; these results do not change the reported primary-endpoint failure.
- Other expense included a $2.26 million first-half loss from the fair-value change in the embedded derivative, partly offset by $0.38 million of warrant-liability fair-value gain and $0.82 million of interest income.
- In the November 2022 private placement, the company issued $15 million of Series B preferred stock and warrants. The preferred stock carries a 7% annual dividend and scheduled monthly amortization/redemption payments. The company paid about $1.64 million on June 1, 2023; subsequent payment deferrals and conversions led to substantial share issuance. As of August 10, 2023, 2,799,249 common shares had been issued to preferred holders, and total common shares issued and outstanding were 10,164,529, versus 7,365,280 at June 30.
- Management estimated cash of approximately $32.5 million as of the filing date would fund projected operating needs and commitments for at least 12 months. It also said additional capital may be needed for further development; equity financing could be dilutive, debt could impose restrictive covenants, and collaboration or licensing could require surrendering rights.
Outlook, risks, and contingencies
- The company is evaluating next steps for Bryostatin-1 and other development programs. A planned Fragile X program remains on FDA clinical hold pending additional pharmacokinetic and pharmacodynamic analyses. A July 2023 agreement with Cleveland Clinic contemplates a Phase 1 MS trial, with estimated costs of approximately $2 million.
- The company disclosed a Nasdaq minimum-bid-price deficiency, with a compliance deadline of October 23, 2023. Compliance required a closing bid price of at least $1 for 10 consecutive business days during the applicable period.
- Management concluded disclosure controls and procedures were ineffective as of June 30, 2023, citing material weaknesses in segregation of duties, financial reporting and close processes, and IT general controls. Management nevertheless stated the financial statements fairly present the company’s financial condition and results.
- Key risks include clinical and regulatory uncertainty, the need for additional capital, dependence on access to bryostatin supply, potential dilution and preferred-stock payment terms, and uncapped indemnification obligations related to the company’s separation from its predecessor. The filing reported no legal proceedings and no material change in risk factors from the 2022 Form 10-K.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Synaptogenix, Inc., not TAO Synergies Inc.
- Review the full preferred-stock certificate and subsequent filings for redemption obligations, payment deferrals, conversion terms, dilution, and the actual number of shares outstanding after August 10, 2023.
- Assess the AD trial’s primary-endpoint failure alongside the subgroup analyses, and look for further clinical plans, protocols, and regulatory updates.
- Track cash use against management’s 12-month liquidity estimate, including planned trial costs and preferred-stock commitments.
- Check subsequent Nasdaq bid-price compliance and management’s remediation of the disclosed control weaknesses.